A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
Public ClinicalTrials.gov record NCT01723826. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open-Label, Long-Term Safety Extension of Phase II Studies ABE4869g and ABE4955g in Patients With Mild to Moderate Alzheimer's Disease
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase II, open-label extension (OLE), multicenter study will evaluate the long-term safety and tolerability of crenezumab in participants with mild to moderate Alzheimer's disease who have participated in and completed the treatment period of the Phase II Study ABE4869g (NCT01343966) or ABE4955g (NCT01397578). Participants who received placebo in Study ABE4869g (NCT01343966) or ABE4955g (NCT01397578) will receive crenezumab. Anticipated time on study treatment is 144 weeks.
Study identification
- NCT ID
- NCT01723826
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 6, 2012
- Primary completion
- Feb 7, 2017
- Completion
- Feb 7, 2017
- Last update posted
- Feb 19, 2020
2012 – 2017
United States locations
- U.S. sites
- 47
- U.S. states
- 20
- U.S. cities
- 45
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Banner Alzheimer's Institute | Phoenix | Arizona | 85006 | — |
| Mayo Clinic | Scottsdale | Arizona | 85259 | — |
| Banner Sun Health Research Insitute | Sun City | Arizona | 85351 | — |
| Pharmacology Research Inst | Encino | California | 91316 | — |
| Margolin Brain Institute | Fresno | California | 93720 | — |
| Univ of CA San Diego; Neurosciences Comp.Alzheimer's | La Jolla | California | 92037 | — |
| USC School of Medicine | Los Angeles | California | 90033 | — |
| University of California Los Angeles (UCLA) | Los Angeles | California | 90095 | — |
| Pharmacology Research Inst | Newport Beach | California | 92660 | — |
| Pacific Neuroscience Med Grp | Oxnard | California | 93030 | — |
| Stanford Univ Medical Center | Palo Alto | California | 94304 | — |
| University of California Davis Medical System | Sacramento | California | 95817 | — |
| Pacific Research Network - PRN | San Diego | California | 92103 | — |
| Uni of California San Francisco | San Francisco | California | 94117 | — |
| Redwood Regional Medical Group | Santa Rosa | California | 95403 | — |
| Yale University | New Haven | Connecticut | 06511 | — |
| Florida Atlantic University; College of Medicine | Boca Raton | Florida | 33431 | — |
| Meridien Research | Brooksville | Florida | 34601 | — |
| Brain Matters Research, Inc. | Delray Beach | Florida | 33445 | — |
| Miami Jewish Health Systems; Clinical Research | Miami | Florida | 33137 | — |
| Collier Neurologic Specialists | Naples | Florida | 34105 | — |
| Bioclinica Research | Orlando | Florida | 32806 | — |
| Axiom Clinical Research of Florida | Tampa | Florida | 33609 | — |
| Premiere Research Institute | West Palm Beach | Florida | 33407 | — |
| Dekalb Neurology Associates | Decatur | Georgia | 30033 | — |
| Rush Alzheimer's Disease Cntr. | Chicago | Illinois | 60612 | — |
| Alexian Brothers Neurosci Inst | Elk Grove Village | Illinois | 60007 | — |
| Indiana Univ School of Med | Indianapolis | Indiana | 46202 | — |
| Louisiana Research Associates | New Orleans | Louisiana | 70114 | — |
| Hattiesburg Clinic | Hattiesburg | Mississippi | 39401 | — |
| Millennium Psychiatric Associates, LLC | St Louis | Missouri | 63132 | — |
| Cleveland Clinic Lou Ruvo; Center for Brain Research | Las Vegas | Nevada | 89106 | — |
| Memory Enhancement Center of America, Inc. | Eatontown | New Jersey | 07724 | — |
| NeuroCognitive Institute | Mount Arlington | New Jersey | 07856 | — |
| Empire Neurology, PC | Latham | New York | 12210 | — |
| Litwin Zucker Research Ctr.; Feinstein Inst. Med. Rsch. | Manhasset | New York | 11030 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| University of Rochester Medical Center; Monroe Community Hospital | Rochester | New York | 14627 | — |
| Investigational Drug Service; Univ of Rochester Medical Ctr | Rochester | New York | 14642 | — |
| Raleigh Neurology Associates | Raleigh | North Carolina | 27607-6520 | — |
| Summit Research Network Inc. | Portland | Oregon | 97210 | — |
| The Clinical Trial Center, LLC | Jenkintown | Pennsylvania | 19046 | — |
| Rhode Island Mood & Memory Research Institute | East Providence | Rhode Island | 02914 | — |
| Butler Hospital | Providence | Rhode Island | 02906 | — |
| Medical Uni of South Carolina | North Charleston | South Carolina | 29425 | — |
| Alzheimers Disease & Memory Disorders Center; Department of Neurology Baylor College of Medicine | Houston | Texas | 77030 | — |
| Clinical Neuroscience Research Associates, Inc. | Bennington | Vermont | 05201 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 39 non-U.S. sites.
Recently updated Alzheimer's Disease trials
Other public records listing Alzheimer's Disease. Sorted by last update posted; newest first. Not a recommendation.
- NCT07717411: A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease Recruiting
- NCT07780383: A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration Not yet recruiting
- NCT07775625: Central Auditory Processing Modulation Underlying Anxiety Reduction Using Clinically Designed Improvisatory Music Recruiting
- NCT06976203: A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) Recruiting
- NCT07688213: A Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease Recruiting
- NCT07721467: Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin Not yet recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01723826, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Feb 19, 2020 · Synced Sep 12, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01723826 live on ClinicalTrials.gov.